Please select the option that best describes you:
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Answer from: Medical Oncologist at Academic Institution
The TRAIN-2 study of non-anthracycline vs. anthracycline-based chemotherapy for HER2 positive disease did include inflammatory breast cancer and found no benefit of anthracycline-based chemotherapy over non-anthracycline based chemo. I would not give anthracycline to a HER2-positive patient just bec...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I agree with Dr. @Shatsky with only a couple of minor possible exceptions. There was a nice discussion on when if ever to use anthracycline in the HER2 curative setting (https://www.themednet.org/question/2229). The cliff notes: Dr. @Soliman discussed the potential benefit in someone with HER2 heter...
Answer from: Medical Oncologist at Community Practice
There is very little reason to use anthracyclines in HER2-positive breast cancer. The one situation I use adriamycin for HER2-positive breast cancer is in a pregnant woman.